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Mesenchymal stromal cells (MSCs), first found in bone marrow (BM), are the structural architects of all organs, participating
in most biological functions. MSCs possess tissue-specific signatures that allow their discrimination according to their origin
and location. Among their multiple functions, MSCs closely interact with immune cells, orchestrating their activity to maintain
overall homeostasis. The phenotype of tissue MSCs residing in the bowel overlaps with myofibroblasts, lining the bottom walls
of intestinal crypts (pericryptal) or interspersed within intestinal submucosa (intercryptal). In Crohn’s disease, intestinal MSCs
are tightly stacked in a chronic inflammatory milieu, which causes their enforced expression of Class II major histocompatibility
complex (MHC). The absence of Class II MHC is a hallmark for immune-modulator and tolerogenic properties of normal MSCs
and, vice versa, the expression of HLA-DR is peculiar to antigen presenting cells, that is, immune-activator cells. Interferon gamma
(IFN𝛾) is responsible for induction of Class II MHC expression on intestinal MSCs. The reversal of myofibroblasts/MSCs from an
immune-modulator to an activator phenotype in Crohn’s disease results in the formation of a fibrotic tube subverting the intestinal
structure. Epithelial metaplastic areas in this context can progress to dysplasia and cancer.
1. Introduction
1.1. Mesenchymal Stromal Cells. Mesenchymal stromal cells
(MSCs) represent the second stem cell population residing
in bone marrow (BM) [1, 2], wherein they provide both
the reservoir for skeletal cell turn-over and “the soil” for
parenchymal cells, that is, hematopoietic stem cells (HSCs),
“the seeds.” MSCs are endowed with extensive proliferation,
three months or longer in vitro; the ability to differentiate
into at least four lineages, osteoblasts, chondroblasts, adipo-
blasts, and reticular stromal cells supporting HSCs; and the
capability to produce large amounts of multiple growth fac-
tors [1, 2] underlying their antiapoptotic, immune-regulator,
and nurturing potential [1–3]. Although MSCs were first
discovered in bone marrow, other tissue-specific MSCs have
been recently recognized and studied based on their antigen
expression signatures and cell differentiation spectra. These
tissue-specificMSCs partly overlapwith pericytes and display
ubiquitous distribution in human tissues as structural cells [3,
4]. We first isolated and characterized MSCs in bone marrow
[1]. Subsequently, we isolated and banked tissue-specific
MSCs from amnion, foetal liver, tonsil, dental pulp, lung, gut
[2, 3], and dermal connective tissue. Bowel MSCs have been
classified functionally and by smooth muscle actin expres-
sion [2, 3]. Pericryptal myofibroblasts are in close contact
with intestinal epithelial stem cells (ISCs) at the bottom
of Lieberku¨hn crypts, wherein they nurture, regulate, and
maintain intestinal stem cells (ISCs) similar to BM-MSCs and
HSCs in the hematopoietic niche. Pericryptal myofibroblasts
hierarchically represent the highest intestinal MSC rank, that
is, share the most “stemness” features with BM-MSCs. Con-
versely, intercryptal MSCs represent a differentiated progeny
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of pericryptal myofibroblasts and are mainly devoted to
structural functions. MSC presence in the intestine might
play a pivotal role in modulating the intestinal immune sys-
tem [5, 6] in terms of tolerance toward commensal micro-
biota [7, 8] and proficiency in recognition and elimination
of the pathogens eventually breaching the mucosal barrier.
Due to the symbiotic nature of the human gut, wherein pro-
karyote microbiota largely outnumber eukaryotic cells, the
importance of adequate homeostasis [2] is paramount.
1.2. Crohn’s Disease. Crohn’s disease (CD) is clinically
characterized by recurrent andmigrating episodes of chronic
inflammation of the digestive mucosa, leading to social
discomfort and bleeding, evolving from mucosal oedema,
thickening, and metaplasia, to granulomas, transmural
lesions, and, finally, stenosis and fistulae. Usually CD is surgi-
cally treated, but residual areas with metaplasia can progress
to dysplasia and, ultimately, to adenocarcinomas. Although
the pathogenesis of CD is complex and still, for themost part,
obscure [9, 10], deregulation of both adaptive and innate
immunity [11, 12] is known to lead, in genetically predisposed
hosts, to an inappropriate response to intestinal microbiota.
The intestinal epithelium is arranged in villi and crypts to
maximize its surface and is composed of ciliated epithelial
cells and other specialized cell types such as goblet cells,
producing a continuous layer of protectivemucus and Paneth
cells releasing 𝛼-defensins. Intercellular and tight junctions
among cells lining the intestinal mucosa contribute to sealing
the intraluminal microbiota from the underlying lamina pro-
pria, while still allowing both the passage of secretory IgA and
the stretching of dendritic cell (DC) projections for continu-
ous sampling andmonitoring of luminal content.The intesti-
nal lamina propria contains a variety of immune cells either
interspersed—mainly innate immune neutrophils, antigen
presenting cells (APCs), and natural killer (NK)/T𝛾/𝛿 cells—
or organized in secondary lymphoid structures like Peyer’s
patches (adaptive immune B and T cells). Adaptive T cells
include proinflammatory T-helper cells (Th1, Th17) and anti-
inflammatory T cells (Th2, Treg).The layer of smoothmuscle
cells underlying the lamina propria, that is, the muscularis
mucosa, is discontinued only by blood and lymphatic vessels
smallest branches. The mesenteric lymph nodes represent
additional secondary lymphoid structures, allowing massive
and on-demand lymphocyte expansion. In CD, the structural
integrity of the intestinal epithelium is ruptured, allowing
excessive amounts of bacteria and oftentimes other pathogens
from the CD-altered consortium to engorge immune cells
in the underlying lamina propria [13]. As a consequence, Th1
and Th17 cell inflammatory response is triggered, character-
ized by the release of inflammatory cytokines (mainly TNF-𝛼,
IL-1𝛼, IFN𝛾, IL-23, and IL-17), expansion and recruitment of
more proinflammatory cells, enlargement of lamina propria,
increased vascularization, and loss of tissue integrity. Gut
epithelium itself seems to exert a selective acting role
in coordinate T-cell responses toward some segmented
filamentous bacteria (SFB) [14]. Microbiota comprises 100
trillion commensal bacteria of more than 1,000 species in
the human gut [15], profoundly affecting the immune profile
of the host, including the balance between proinflammatory
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Figure 1: HLA-DR levels in Crohn’s-derived versus bowel- and
bone marrow-derived MSCs. Dot plot of normalized fluorescence
intensities from flow cytometric analysis of HLA-DR expression in
Crohn, colon, and bone marrow MSCs. MSCs obtained from colon
and bone marrow samples are consistently negative for HLA-DR, a
major histocompatibility complex (MHC) Class II antigen, whereas
Crohn’s-derived MSCs constitutively express statistically significant
levels. The antibody used was R-phycoerythrin-labeled mouse anti-
human HLA-DR (Becton-Dickinson). Mean fluorescence intensity
(MFI) of isotype control was subtracted to MFI from HLA-DR
intensity to generate the plotted normalized intensities. 𝑝 values
were obtained by performing Student’s 𝑡-test via SAS JMP v10
software (SAS Institute Inc., Cary, NC).
T-helper cells (Th1,Th17) and anti-inflammatory T cells (Th2,
Treg).Th1 cells aremainly producing IFN𝛾. An abnormalTh1
response, triggered by increased mucosal levels of IL-18 and
IL-12, has been associated with CD while a Th2 response is
characterized by secretion of IL-4, IL-5, and IL-13. Th17 cells
are able to produce IL-17 and IFN𝛾 depending on the context.
Treg cells have a similar secretory plasticity and comprise
a series of subsets, including CD4+, CD25+, and FoxP3+
cells, and induced-Treg. Comprehension of the mechanisms
eventually involved in the regulation, by MSCs, of IFN𝛾-
producing Th17 cells or Treg cells, deserves future study.
Moreover, T𝛾/𝛿 cells have been reported to contribute to
chronic inflammation through a rapid and intense produc-
tion of IFN𝛾 [16, 17]. Recent evidence indicates that, in
addition to conventional T cells, T𝛾/𝛿 cells may represent a
major innate source of IL-17 in response to bacterial infection
[18]. Moreover, T𝛾/𝛿 cells have been shown to exacerbate
chronic inflammation by suppressing Treg cell function [19].
1.3. Mesenchymal Stromal Cells Immunity. Under physiolog-
ical conditions, MSCs are known to modulate the function
of diverse types of immune cells, both adaptive [20, 21]
and innate [16, 17, 22]. However, only recently has their
role in an inflammatory or neoplastic microenvironment
undergone scrutiny [23]. MSC exhaustion and failure to
control CD chronic inflammation result in their IL33-
induced expansion/differentiation into fibrotic scar tissue,
which has improperly been defined as “creeping fat” [24].
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Figure 2: Immunofluorescence analysis of Crohn’s disease surgical specimens. In contrast to the typical structure of normal distal intestine
mucosa, Crohn’s disease sections have a totally subverted architecture wherein the presence of some CD146+ cells expressing high levels
of HLA-DR (white arrows) is detected, in close proximity to or interspersed between smaller HLA-DR+ cells. Normal colonic mucosa and
Crohn’s disease specimens were obtained from patients who signed an informed consent before undergoing surgical resection. Tissues were
fixed in PFA 4% o/n at +4∘C, embedded, frozen in OCT, and stored at −80∘C. Thick sections (15𝜇m) were cut on a cryotome and processed
for immunofluorescence staining. Permeabilization was performed with 0.5% Triton X-100 in PBS for 30󸀠, at room temperature. A blocking
step was performed using 40𝜇g/mL mouse IgG in 3% BSA (PBS) for 2 h at RT, and subsequent incubation with primary antibodies was
carried out for 16h at +4∘C. Primary antibodies used were FITC conjugated mouse anti-CD146 (Biocytex) and R phycoerythrin-labeled
mouse anti-human HLA-DR (Becton-Dickinson). The final step, before mounting the slides, was incubation with a TRITC-conjugated goat
anti-PE secondary antibody (Aviva Systems Biology), for 2 h at 37∘C.Nuclear staining was executed adding RNAse andDAPI to the secondary
antibody incubationmix. Images were acquired with an Olympus FV-1000 spectral confocal microscope, equipped with an UPLFLN 40x 1.30
NA oil immersion objective. Scale bars correspond to 50 𝜇m.
The understanding of intestinal MSC function in orchestrat-
ing gut immune responses might lead to the development of
MSC targeted-specific drugs. The interest for MSC role in
immunity derived many clinical studies. Out of 25 clinical
trials with MSCs in Crohn’s disease, 5 were completed
with bone marrow MSCs and 7 are active or recruiting,
7 were completed with adipose-derived MSCs and 2 are
active/recruiting, 1 was completed and 2 are active/recruiting
with umbilical cord MSCs, and, finally, 1 was completed
with placental MSCs (https://www.clinicaltrials.gov/). Over-
all these studies have demonstrated the beneficial effects
of MSC systemic administration in refractory CD patients,
devoid of toxicity and not requiring the ablation of the
recipient’s immune system [25]. The efficacy of this replace-
ment therapy suggests that endogenous colonic MSCs could
be reverted, damaged, or exhausted in the areas affected
by CD, and that the infused MSCs are recruited to the
inflamed lesions where they home and eventually restore
homeostasis. However, time course studies on MSC action
are lacking as well as information on their long-term safety.
HowMSCs behave or react when exposed to the CD chronic
inflammatory milieu, including their liaison with Th/Treg or
mucosal T𝛾/𝛿 cells [16, 17, 26–28], remains unresolved. Expo-
sure of MSCs to inflammatory cytokines has been defined
as licensing, but licensed MSC functional comparisons with
na¨ıve MSCs remain inconclusive [29–32].
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Figure 3: Dot plot analysis of C-MSCs treated with graded amount of IFN𝛾 ng/ml for 72 h. Bowel MSCs were stained with PE-labeled HLA-
DR mAB (Pharmingen) and analysed with FACSCanto (Becton-Dickinson).
2. Results/Discussion
Wehave recently isolated and banked severalMSC lines from
most human organs, in both foetal stages and adulthood.
Among them 9 bowel MSC lines from normal surgical
specimens have been described. They have been extensively
characterized and compared to canonical BM-MSC lines,
showing a mostly shared identity, yet distinguishable by
subtle tissue-specific features [1, 3, 4]. An important hall-
mark of MSCs, isolated from all tissues, is the absence, in
physiological conditions, of HLA-DR expression, which has
been linked to both their modulator activity on immune cells
and their tolerogenicity as described in [3]. Conversely, our
new results show that intestinal MSCs from CD, isolated
from endoscopic biopsies, display a constant upmodulation
of Class II MHC (Figure S1, in Supplementary Material
available online at https://doi.org/10.1155/2017/8482326, BM
versus intestinal versus Crohn’s MSCs), whose expression
might indicate a diversion from the normal MSC immune-
modulator function, to an opposite stimulatory APC func-
tion. It is noteworthy that HLA-ABC (Class I MHC) expres-
sion is unchanged (not shown), being highly expressed by
all MSCs (see Table 1 in [3]). HLA-DR overexpression has
been observed in 3 intestinal MSC lines (Figure 1, Figures S1
and S2) derived from CD and confirmed in two additional
CD bowel sections by confocal microscopy (Figure 2). The
CD-MSC expression of Class II MHC and the switch from
negative to positive regulation of immune cells [29] might
play a significant role in CD pathogenesis. After treatment
of normal intestinal MSCs with a series of inflammatory
cytokines, we identified IFN𝛾 as the main culprit for HLA-
DR expression in CD-MSC (Figure 3). Notably, TNF𝛼 had
no effect on Class II HLA expression (data not shown). It
is noteworthy that in one patient different biopsies showing
increasing levels of inflammation generated MSCs lines with
increasing HLA-DR expression (Figure S2, lanes 1 to 4).
We can speculate that once the disease has started, and the
mucosal barrier integrity has been breached, allowing the
bacteria from the intestinal lumen to enter the submucosal
layer, immune cells start to fight bacterial cells and elicit an
inflammatory response. When this response is prolonged,
the high levels of local inflammatory cytokines damage
resident MSCs, which, turning on HLA-DR, change their
function from immune-modulators to immune-stimulators,
as antigen presenting cells, triggering the maintenance of the
inflammation in a chronic state. Our interest in intestinal
MSCs stems from their identification in foetal bowel [33]
and from their potential role in maintaining the intestinal
homeostasis [34]. In intestinal sections, residentMSCs form a
delicate net enveloping crypts within the lamina propria [3].
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Nine subclonal CD146+ MSC lines were derived and char-
acterized from adult intestinal biopsies, in addition to other
MSC lines from 6 different human tissues. We identified
and characterized two subtypes of gut MSC lines, that is,
one subtype lining the bottom walls of intestinal crypts and
another forming a cellular network between the crypts as
demonstrated in publication [3]. Similar to their BM coun-
terpart, intestinal MSCs are able to modulate immune cells,
in vitro, and to inhibit allogeneic T-cell proliferation induced
by mature myeloid-derived dendritic cells (MDDCs). This
inhibition is mediated by the enhanced production of anti-
inflammatory IL-10 and by the inhibition of proinflammatory
IL-12 production. Our data highlight a specific role of gut
MSCs in controlling intestinal immunity and inflammation
[3]. Additionally, in this manuscript, we report the isolation
of bowel MSCs from 3 positive staging biopsies for CD
and 2 surgical specimens of colon cancer [35]. It would be
extremely interesting to study the live interaction of intestinal
MSCs with immune cells in space and time under normal
and pathophysiological conditions. Such analyses could be
performed either in vitro by exploiting human-derived three-
dimensional gut tissue models or in vivo by means of mouse
models of inflammatory bowel disease.
It is noteworthy that Crohn’s disease possible progression
to colon adenocarcinoma confers upon it the features of
a natural model to study the development of cancer from
a chronic inflammation. This includes the role of immune
cells operating in a specific microenvironment such as the
colonic walls. Colon MSCs maintain their spurious HLA-DR
expression in the context of adenocarcinoma as shown in a
representative colon cancer MSC line (Figure S2 lane 5). It is
apparent thatHLA-DRupregulation in gutMSCs represents a
link between a chronic inflammatory disease, Crohn’s disease,
and cancer, colon adenocarcinoma. Emerging evidences on
Crohn’s disease treated with new molecularly tailored drugs
indicate the occurrence of Hepatosplenic T-Cell Lymphoma
(HSTCL), which probably follow a different pathogenesis
going beyond the purpose of this article.
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